Interscalene brachial plexus block is the standard regional anesthetic technique for shoulder surgery, providing reliable perioperative analgesia while reducing opioid consumption and facilitating earlier discharge. To perform it, healthcare provides must select an appropriate long-acting local anesthetic. In shoulder surgery, bupivacaine and ropivacaine are the two agents most widely used for the interscalene block , and although both belong to the aminoamide class of local anesthetics and share a similar mechanism of action, they differ in important pharmacological and safety characteristics. Understanding these differences is essential for clinicians seeking to optimize analgesic outcomes while minimizing risk.
Ropivacaine was introduced in part as a response to well-documented concerns about bupivacaine’s cardiotoxic and neurotoxic potential following inadvertent intravascular injection. As an S-enantiomer, ropivacaine demonstrates less cardiac depression and fewer central nervous system effects when administered intravenously, offering a theoretical safety advantage in procedures requiring large volumes of local anesthetic, such as interscalene block¹. This safety profile initially prompted investigation into whether ropivacaine could serve as a clinically equivalent substitute for bupivacaine without compromising block quality.
An early study compared 0.5% bupivacaine, 0.5% ropivacaine, and 0.75% ropivacaine interscalene block in a double-blind, randomized trial of 75 patients undergoing outpatient shoulder surgery¹. All three groups demonstrated a mean sensory block onset time of under six minutes, with no statistically significant differences in onset or duration across any recovery measure. Analgesic duration, assessed by time to first narcotic use and return of full shoulder sensation, was comparable among groups, ranging from 12 to 15 hours. Notably, increasing the ropivacaine concentration from 0.5% to 0.75% conferred no additional benefit, suggesting that the risk associated with higher total dosage is unnecessary when equivalent efficacy is achievable at lower concentrations.
Another early study compared higher concentrations of ropivacaine—0.75% and 1%—against 0.5% bupivacaine using a smaller injection volume of 20 mL in 45 patients receiving an interscalene nerve block and undergoing elective shoulder surgery². Their results diverged in one meaningful respect: surgical readiness was achieved significantly faster with ropivacaine 1% (10 ± 5 minutes) and ropivacaine 0.75% (15 ± 8 minutes) compared with bupivacaine 0.5% (28 ± 15 minutes). However, this onset advantage did not translate into superior postoperative analgesia, as time to first analgesic request was nearly identical across all three groups at approximately 10.7 to 10.9 hours. These findings suggest that when faster surgical block onset is clinically desirable, higher concentrations of ropivacaine may offer a meaningful advantage over standard bupivacaine.
Eroglu et al. examined the two agents at equal volume and concentration, with 0.15% bupivacaine or 0.15% ropivacaine following an initial block with 30 mL of 0.5% of the same agent in 44 patients³. Onset times, pain scores, total local anesthetic consumption, rescue analgesia requirements, side effect profiles, and patient satisfaction were all statistically equivalent between groups.
Further research has investigated the impact of adjunctive agents on block efficacy. A randomized trial of 218 patients introduced perineural dexamethasone as a variable⁴. Without adjuncts, plain bupivacaine provided a longer median block duration than plain ropivacaine (14.8 hours vs. 11.8 hours), a statistically significant difference. However, dexamethasone prolonged analgesia in both groups to approximately 22 hours, nearly eliminating this gap. Crucially, the augmenting effect of dexamethasone was significantly stronger with ropivacaine than with bupivacaine, suggesting a pharmacodynamic interaction that may guide agent selection when adjuncts are planned.
Taken together, this body of evidence supports several practical conclusions. When used at equivalent concentrations and volumes, bupivacaine and ropivacaine produce comparable interscalene block quality for shoulder surgery. However, clinicians seeking faster surgical onset may benefit from higher ropivacaine concentrations. Furthermore, incorporating dexamethasone as an adjunct can significantly extend block duration with both agents, though the effect may be augmented with ropivacaine. Block selection should ultimately be individualized based on patient risk factors, procedural demands, and institutional familiarity with each agent.
References
1. Klein, S. M. et al. A comparison of 0.5% bupivacaine, 0.5% ropivacaine, and 0.75% ropivacaine for interscalene brachial plexus block. Anesth. Analg. 87, 1316–1319 (1998). https://pubmed.ncbi.nlm.nih.gov/9842819/
2. Casati, A. et al. A clinical comparison of ropivacaine 0.75%, ropivacaine 1% or bupivacaine 0.5% for interscalene brachial plexus anaesthesia. Eur. J. Anaesthesiol. 16, 784–789 (1999). https://pubmed.ncbi.nlm.nih.gov/10713873/
3. Eroglu, A. et al. A clinical comparison of equal concentration and volume of ropivacaine and bupivacaine for interscalene brachial plexus anesthesia and analgesia in shoulder surgery. Reg. Anesth. Pain Med. 29, 539–543 (2004). https://pubmed.ncbi.nlm.nih.gov/15635512/
4. Cummings, K. C. et al. Effect of dexamethasone on the duration of interscalene nerve blocks with ropivacaine or bupivacaine. Br. J. Anaesth. 107, 446–453 (2011). https://academic.oup.com/bja/article-abstract/107/3/446/256625
